Cediranib News and Research

RSS
Cediranib is a substance being studied in the treatment of some types of cancer. Cediranib may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of antiangiogenesis agent and a type of vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor. Also called AZD2171 and Recentin.
Study compares cediranib plus olaparib and standard of care therapy for platinum-sensitive ovarian cancer

Study compares cediranib plus olaparib and standard of care therapy for platinum-sensitive ovarian cancer

Study reveals how glioblastomas resist the effects of antiangiogenic drugs

Study reveals how glioblastomas resist the effects of antiangiogenic drugs

AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016

AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016

New drug combination may be effective against malignant melanoma

New drug combination may be effective against malignant melanoma

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Experimental drug may help fight cervical cancer

Experimental drug may help fight cervical cancer

Cediranib combined with chemotherapy improves survival in recurrent cervical cancer

Cediranib combined with chemotherapy improves survival in recurrent cervical cancer

Elderly mRCC patients should not be excluded from targeted therapy option

Elderly mRCC patients should not be excluded from targeted therapy option

Women with recurrent ovarian cancer survive longer after treatment with cediranib

Women with recurrent ovarian cancer survive longer after treatment with cediranib

New data analyzing technique via MR imaging identify tumors' response to anti-angiogenesis therapy

New data analyzing technique via MR imaging identify tumors' response to anti-angiogenesis therapy

Patients with ASPS appear to benefit from anti-cancer drug, cediranib

Patients with ASPS appear to benefit from anti-cancer drug, cediranib

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

New biomarker predicts brain tumor's response to cediranib therapy

New biomarker predicts brain tumor's response to cediranib therapy

Angiogenesis inhibitor improves glioblastoma survival by reducing edema

Angiogenesis inhibitor improves glioblastoma survival by reducing edema

Drugs in the pipeline: new therapies that could change treatment strategies

Drugs in the pipeline: new therapies that could change treatment strategies